Document:

EX-10.04

 Exhibit 10.04 
 Execution Version 
 SERVICES AGREEMENT 

This Services Agreement (the “Agreement”) is entered into as of March 7, 2013 (the “Effective
Date”) by and between SORRENTO THERAPEUTICS, INC., a Delaware corporation (“STI”) having an office at 6042 Cornerstone Court West, Suite B, San Diego, California 92121
(“STI”) and IGDRASOL, INC., a Delaware corporation (“IgDraSol”) having an office at 11100 Warner Avenue, Suite 266, Fountain Valley,
California 92708. STI and IgDraSol may be referred to herein individually as a “Party” and collectively as the “Parties.” 
 1. DEFINITIONS. As used in this Agreement: 
 1.1
“Anti-Corruption Law” means all international, national, state and local laws, statutes, rules, and regulations regarding corruption, bribery, ethical business conduct, money laundering, political contributions, gifts and gratuities,
or lawful expenses to public officials and private persons, agency relationships, commissions, lobbying, books and records, and financial controls. 
 1.2 “Applicable Laws” means all international, national, state and local laws, statutes, rules, and regulations that are applicable to a Party’s activities hereunder, including
without limitation Good Clinical Practices. 
 1.3 “Deliverables” means the items to be provided or actually
provided by IgDraSol to STI under this Agreement, including items specifically designated or characterized as deliverables in the Development Plan mutually agreed in writing by the Parties. 

1.4 “Development Plan” means the development plan and related budget for research and development of the Products and
related compounds attached hereto as Exhibit A, as may be amended from time to time pursuant to Section 2.1. 

1.5 “FCPA” means the U.S. Foreign Corrupt Practices Act (15 U.S.C. Section 78dd-1, et seq.) as may be
amended or supplemented from time to time. 
 1.6 “FDA” means the United States Food and Drug Administration or
any successor entity thereto. 
 1.7 “Good Clinical Practices” or “GCPs” means, as applicable,
the then-current Good Clinical Practices as such term is defined from time to time by the FDA or other relevant governmental authority having jurisdiction over the development, manufacture or sale of the Products pursuant to its regulations,
guidelines or otherwise, as applicable. 
 1.8 “Intellectual Property” or “IP” means ideas, concepts,
discoveries, inventions, developments, know-how, trade secrets, techniques, methodologies, modifications, innovations, improvements, writings, documentation, electronic code, data and rights (whether or not protectable under state, federal or
foreign patent, trademark, copyright or similar laws) or the like, whether or not written or otherwise fixed in any form or medium, regardless of the media on which contained and whether or not patentable or copyrightable. 

  
 1 

 Execution Version 
  

 1.9 “Materials” means any tangible materials supplied by STI to
IgDraSol for use in connection with the Services. 
 1.10 “Products” means potential compounds from STI’s
proprietary antibody library. 
 1.11 “Records and Accounts” has the meaning set forth in Section 5.

 1.12 “Research IP” has the meaning set forth in Section 6.3. 

1.13 “Services” means the research and development services to be provided by IgDraSol hereunder, as specifically set
forth in the Development Plan. 
 1.14 “Services Manager” has the meaning set forth in Section 2.3.

 1.15 “Specifications” means any protocols, procedures, process parameters, analytical tests and other
specifications for the Services and Deliverables included in the Development Plan. 
 1.16 “STI Contact” has
the meaning set forth in Section 2.3. 
 2. SERVICES 

2.1 Development Plan. Effective March 1, 2013, the Parties have agreed to the Development Plan that specifies the Services to
be performed and Deliverables to be provided by IgDraSol hereunder, as well as the terms and conditions (including Specifications, delivery and performance schedules, fees and payment schedule) under which IgDraSol will perform such Services. STI
hereby consents to IgDraSol’s use of certain Intellectual Property of STI or its licensors, relating to the Products and as specified in the Development Plan, solely as necessary to perform the Services under the Development Plan. In the event
of any conflict between this Agreement and the Development Plan, this Agreement shall control. The Development Plan may only be amended by written agreement of both Parties. 
 2.2 Performance of Services. IgDraSol shall perform the Services in accordance with the terms of this Agreement, the Development Plan, and all Applicable Laws. IgDraSol shall provide, at its own
expense, a place of work for its employees performing the Services and all equipment, tools and other materials necessary to complete the Development Plan. 
 2.3 Services Manager. IgDraSol shall appoint one of its employees as its “Services Manager” for the Services. The Services Manager shall be responsible for all aspects of the
Services hereunder through completion of such Services. Such Services Manager shall coordinate with the person designated by STI for coordination of the Services as its “STI Contact” for the performance of the Services. Unless
otherwise agreed, all communications between STI and IgDraSol regarding the conduct of the Services pursuant to the Development Plan shall be addressed between such Services Manager and STI Contact. 

2.4 Timelines. IgDraSol shall use commercially reasonable efforts to comply with any timelines, schedules or target dates for
delivering to STI the Deliverables and completing the Services or any portion thereof as set forth in the Development Plan. If at any time IgDraSol 

  
 2 

 Execution Version 
  

 
anticipates a delay in meeting such timelines, IgDraSol shall promptly notify STI in writing of such anticipated delay and the estimated duration of such delay, and the Parties shall negotiate in
a timely, good faith manner to resolve such anticipated delay. 
 2.5 Records. IgDraSol shall create and maintain written
records of the data and other information generated or recorded in the performance of the Services and all other information related to the performance of the Services in a timely, accurate, complete, and legible manner. IgDraSol shall maintain such
records in compliance with the terms and conditions of this Agreement, the Development Plan, and Applicable Laws. IgDraSol shall not destroy any records without STI’s prior written consent. During the course of conducting the Services, IgDraSol
shall, at STI’s request and expense, provide STI with copies of the records. Promptly upon expiration or termination of this Agreement, IgDraSol shall transfer to STI copies of all records requested by STI. 

2.6 Subcontracting. IgDraSol shall not subcontract or otherwise delegate any of its obligations under this Agreement without
STI’s express prior written consent, such consent not to be unreasonably withheld. Upon receipt of such consent, before allowing any such subcontractor to begin performing such task, IgDraSol shall enter into a written agreement with such
subcontractor that obligates such subcontractor to be bound by the applicable terms and conditions of this Agreement, in the same manner as such terms and conditions apply to IgDraSol. All such subcontractors shall be retained directly by IgDraSol
and no contractual relationship shall be created between STI and subcontractors. STI shall have no obligation to pay any subcontractor, and IgDraSol shall do so using the payment submitted by STI as part of the overall budget set forth in the
Development Plan. As between STI and IgDraSol, IgDraSol shall be the Party obligated and responsible for the performance of all Services hereunder, regardless of whether any portion of such Services is delegated pursuant to this Section 2.6.

 2.7 Employees. Subject to Section 2.6, IgDraSol shall conduct the Services through its employees and consultants
approved in advance by STI. IgDraSol shall ensure that each of its employees and consultants who will have access to any Confidential Information or perform any Services are bound by contractual obligations (either through their employment contract,
consultant contract or other written agreement with IgDraSol) that protects STI’s rights and interests to at least the same degree as this Agreement. 
 2.8 Materials. STI shall be responsible for providing IgDraSol with sufficient amounts of the Materials for IgDraSol to perform the Services. Title to the Materials shall remain with STI. IgDraSol
shall use the Materials solely to perform the Services under the Development Plan and for no other purpose, and in compliance with STI’s instructions and Applicable Laws. IgDraSol shall not sell, transfer, disclose or otherwise provide access
to the Materials to any person or entity without the prior written consent of STI. Upon completion of the applicable Services or earlier upon STI’s request, IgDraSol shall, according to STI’s instructions, return the Materials to STI or
destroy the Materials and certify such destruction in writing. 
 2.9 Reports. Upon completion of all Services under the
Development Plan, or at such other times as set forth in the Development Plan, IgDraSol shall provide STI with a written report summarizing all records and Services completed to date, in both electronic and hard copy. 

  
 3 

 Execution Version 
  

 3. INDEPENDENT CONTRACTOR RELATIONSHIP.
IgDraSol’s relation to STI under this Agreement is that of an independent contractor. Nothing in this Agreement is intended or should be construed to create a partnership, joint venture, or employer-employee relationship between STI and any of
IgDraSol’s employees or agents. Neither Party is the agent of the other Party and neither Party is authorized, and must not represent to any third party that it is authorized, to make any commitment or otherwise act on behalf of the other
Party. 
 4. COMPENSATION. Subject to the terms and conditions of this Agreement, on the Effective Date, STI shall
pay IgDraSol the fees specified in the Development Plan (“Fees”) as IgDraSol’s sole and complete compensation for all Services (including Deliverables, and Intellectual Property rights) provided by IgDraSol under this
Agreement. No other fees shall be owed by STI under this Agreement. Such Fees are contemplated to include payments for full time employees and out-of-pocket expenses. 
 5. AUDITS. IgDraSol shall maintain accurate and complete records and accounts relating to Services provided hereunder, and, in accordance with generally-accepted accounting
principles, complete and accurate records of employee time as well as expenses incurred sufficient to document the Fees invoiced to STI for at least three (3) years following the date of the invoice (“Records and Accounts”).
Upon request by STI provided with reasonable prior notice, IgDraSol shall allow STI or STI’s authorized representatives to visit IgDraSol’s facilities during normal business hours to observe and verify IgDraSol’s compliance with this
Agreement, review the Records and Accounts, inspect those facilities of IgDraSol which are being utilized in the Services, and/or to make copies of relevant records. 
 6. INTELLECTUAL PROPERTY 
 6.1 STI Intellectual Property. Subject to the rights granted in Section 2.1, STI shall retain all right, title and interest in and to all Intellectual Property owned or known by STI prior to
the Effective Date or made or acquired by STI during the Term. 
 6.2 IgDraSol Intellectual Property. Subject to the
licenses set forth in Section 6.4 and except as otherwise expressly assigned or licensed pursuant to a separate agreement, IgDraSol shall retain all right, title and interest in and to all Intellectual Property owned by IgDraSol prior to the
Effective Date or made by IgDraSol during the Term independent of this Agreement. 
 6.3 Research Intellectual Property.

 6.3.1 Ownership. STI shall own all right, title and interest in and to the Deliverables and all intellectual property
rights and know-how therein, as well as all Intellectual Property or know-how made or developed solely or jointly by IgDraSol in the course of performing the Services or otherwise under this Agreement (collectively, the “Research
IP”). STI grants IgDraSol a non-exclusive, royalty-free, non-transferable, perpetual license to use Deliverables solely for internal quality assurance of regulated laboratory operations. 

6.3.2 Disclosure and Assignment. IgDraSol shall notify STI in writing of any and all Research IP promptly after its conception,
development or reduction to practice. IgDraSol hereby assigns and transfers to STI all of its right, title and interest in and to the 

  
 4 

 Execution Version 
  

 
Research IP and agrees to take, and to cause its employees, agents, and consultants to take, all further acts reasonably required to evidence such assignment and transfer to STI, at STI’s
reasonable expense. STI shall have the sole right and discretion, at its expense, to prepare, file, prosecute and maintain any patent applications and patents claiming the Research IP. 

6.4 License Grants to STI. IgDraSol hereby grants to STI a non-exclusive, perpetual, irrevocable, worldwide, royalty-free, fully
paid, sub licensable (through multiple tiers) license under all IP owned by IgDraSol incorporated into the Deliverables to exploit the Deliverables. 
 7. CONFIDENTIALITY 
 7.1
Confidential Information. All information that is disclosed or provided by one Party to the other Party pursuant to this Agreement shall be “Confidential Information” of the disclosing Party. Confidential Information may be
disclosed by either Party in oral, written or other tangible form or otherwise learned by the receiving Party under this Agreement, and may include, but not be limited to, the disclosing Party’s research, development, preclinical and clinical
programs, data and results; pharmaceutical or biologic candidates and products; inventions, works of authorship, trade secrets, processes, conceptions, formulas, patents, patent applications, and licenses; business, product, marketing, sales,
scientific and technical strategies, programs and results, including costs and prices; suppliers, manufacturers, customers, market data, personnel, and consultants; and other confidential or proprietary matters related to the Services. In addition,
all Research IP, records and reports delivered under Section 2.9 shall be deemed Confidential Information of STI. Except to the extent expressly authorized by this Agreement or by the disclosing Party in writing, during the Term and for
                       thereafter, each Party shall maintain in strict trust and confidence and shall not disclose to any third party or use for
any purpose other than as provided for in this Agreement any Confidential Information of the other Party. IgDraSol may use the Confidential Information of STI only to the extent required to perform the Services and for no other purpose. Neither
Party shall use the Confidential Information of the other Party for any purpose or in any manner that would constitute a violation of Applicable Laws. 
 7.2 Exceptions. The obligations of confidentiality and nonuse set forth in Section 7.1 shall not apply to any specific portion of information that a Party can demonstrate by competent written
proof: (a) is in the public domain or comes into the public domain through no fault of the receiving Party; (b) is furnished to the receiving Party by a third party rightfully in possession of such information not subject to a duty of
confidentiality with respect thereto, as shown by the receiving Party’s written records contemporaneous with such third party disclosure; (c) is already known by the receiving Party at the time of receiving such Confidential Information
and as evidenced by the receiving Party’s prior written records; or (d) is independently developed by the receiving Party’s employee or agent who had no access to the other Party’s Confidential Information, as demonstrated by the
receiving Party’s independent written records contemporaneous with such development. 
 7.3 Authorized Disclosure.
Notwithstanding the foregoing in this Section 7, a Party may disclose certain Confidential Information of the other Party to the extent such disclosure is required by Applicable Laws, or pursuant to a valid order of a court or other
governmental body having jurisdiction; provided, however, that the receiving Party provides the disclosing Party 

  
 5 

 Execution Version 
  

 
with reasonable prior written notice of such disclosure and reasonable assistance in obtaining a protective order or confidential treatment preventing or limiting the disclosure and/or requiring
that such Confidential Information so disclosed be used only for the purposes for which the Applicable Law required, or for which the order was issued. 
 7.4 Third Party Confidential Information. Neither Party shall disclose to the other Party any confidential or proprietary information that belongs to any third party unless the disclosing Party
first obtains the consent of such third party. The disclosing Party shall not represent to receiving Party as being unrestricted any designs, plans, models, samples, or other writings or products that disclosing Party knows are covered by valid
patent, copyright, or other form of intellectual property protection belonging to a third party. 
 7.5 Return of
Confidential Information. Upon termination or expiration of the Agreement, or upon written request of disclosing Party, receiving Party shall promptly return or destroy all documents, notes and other tangible materials representing disclosing
Party’s Confidential Information and all copies thereof; provided, however, that receiving Party may retain a single archival copy of such Confidential Information for the sole purpose of facilitating compliance with the surviving
provisions of this Agreement. 
 7.6 Injunctive Relief. The Parties expressly acknowledge and agree that any breach or
threatened breach of this Section 7 by one Party may cause immediate and irreparable harm to the other Party that may not be adequately compensated by damages. Each Party therefore agrees that in the event of such breach or threatened breach by
receiving Party, and in addition to any remedies available at law, disclosing Party shall have the right to seek equitable and injunctive relief, without bond, in connection with such a breach or threatened breach. 

8. REPRESENTATIONS AND WARRANTIES 

8.1 Due Authorization. Each Party represents and warrants that (a) it has the full power and authority to enter into this
Agreement, (b) this Agreement has been duly authorized, (c) this Agreement is binding upon it, and (d) the execution of and its performance under this Agreement is not inconsistent with any contractual obligation with a third party.

 8.2 No Debarred Person. IgDraSol represents and warrants that it will not employ, contract with, or retain any person
directly or indirectly to perform the Services under this Agreement if such person is under investigation by the FDA for debarment or is presently debarred by the FDA pursuant to the Generic Drug Enforcement Act of 1992, as amended (21 U.S.C. §
301, et seq.). In addition, IgDraSol represents and warrants that it has not engaged in any conduct or activity that could lead to any such debarment actions. If during the Term, IgDraSol or any person employed or retained by it to perform
the Services (a) comes under investigation by the FDA for a debarment action, (b) is debarred, or (c) engages in any conduct or activity that could lead to debarment, IgDraSol shall immediately notify STI of same. 

8.3 No Infringement. Each Party represents and warrants that to its knowledge, the performance of the Services will not infringe
or misappropriate, and the Deliverables or any element thereof will not infringe or misappropriate, any intellectual property right of any third party. 

  
 6 

 Execution Version 
  

 8.4 Warranty Disclaimer. EXCEPT AS EXPRESSLY SET FORTH IN THIS SECTION 8, EACH
PARTY HEREBY DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. 
 8.5 Compliance with Law. Each Party represents and warrants that in its performance of this Agreement, (a) it will comply with all Applicable Laws, including the FCPA and other applicable
Anti-Corruption Laws; and (b) it shall take no action that would cause the other Party to be in violation of the FCPA or other applicable Anti-Corruption Laws. 
 9. INDEMNIFICATION; LIMITATION OF LIABILITY 

9.1 By IgDraSol. IgDraSol shall indemnify, defend and hold harmless STI and its affiliates and their respective directors,
officers, employees, and agents (the “STI Indemnitees”) from and against any and all costs, expenses, liabilities, damages, losses and harm (including reasonable legal expenses and attorneys’ fees) arising out of or resulting
from any third party suits, claims, actions, or demands (collectively, “Claims”), to the extent resulting from or caused by: (a) the negligence, recklessness or willful misconduct of any IgDraSol Indemnitee; or
(b) IgDraSol’s breach of its obligations, warranties, or representations under this Agreement, except in each case to the extent that a Claim arises out of or results from the negligence, recklessness or willful misconduct of any STI
Indemnitee or STI’s breach of its obligations, warranties, or representations under this Agreement. 
 9.2 By STI.
STI shall indemnify, defend and hold harmless IgDraSol and its directors, officers, employees, and agents (the “IgDraSol Indemnitees”) from and against any and all Claims to the extent resulting from or caused by: (a) the
negligence, recklessness or willful misconduct of any STI Indemnitee; (b) STI’s breach of its obligations, warranties or representations under this Agreement; or (c) STI’s use of the Deliverables, except in each case to the
extent that a Claim arises out of or results from the negligence, recklessness or willful misconduct of any IgDraSol Indemnitee or IgDraSol’s breach of its obligations, warranties, or representations under this Agreement. 

9.3 Indemnification Conditions and Procedures. Each Party’s agreement to indemnify, defend and hold harmless the other Party
is conditioned on the indemnified Party: (a) providing written notice to the indemnifying Party of any claim or demand for which is it seeking indemnification hereunder promptly after the indemnified Party has knowledge of such claim;
(b) permitting the indemnifying party to assume full responsibility to investigate, prepare for and defend against any such claim or demand, except that the indemnified Party may cooperate in the defense at its expense using its own counsel;
(c) assisting the indemnifying Party, at the indemnifying Party’s reasonable expense, in the investigation of, preparing for and defense of any such claim or demand; and (d) not compromising or settling such claim or demand without
the indemnifying Party’s prior written consent. 
 9.4 Limitation of Liability. EXCEPT FOR DAMAGES AVAILABLE FOR
BREACHES OF CONFIDENTIALITY OBLIGATIONS UNDER SECTION 7 AND THE INDEMNIFICATION RIGHTS AND OBLIGATIONS UNDER SECTION 9, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE OR INDIRECT DAMAGES ARISING
FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. 

  
 7 

 Execution Version 
  

 10. TERM AND TERMINATION

 10.1 Term. The term of this Agreement (the “Term”) shall commence on the Effective Date and, unless
earlier terminated in accordance with this Section 10, shall continue for                          after the Effective Date.

 10.2 Termination for Breach. Either Party may terminate this Agreement immediately upon written notice to the other
Party if the other Party breaches this Agreement and does not fully cure the breach to the non-breaching Party’s satisfaction within         
               after such Party gives notice of the breach to the other Party. 
 10.3 Effects of Termination 
 10.3.1 Survival. Sections 1, 2.8, 3,
6, 7, 9 (solely to the extent the Claims can be attributed to action or omission during the Term), 10 and 11 shall survive any termination or expiration of this Agreement. Termination or expiration of this Agreement shall not affect either
Party’s liability for any breach of this Agreement it may have committed before such expiration or termination. 

10.3.2 Retention by IgDraSol of Certain STI Property. Upon termination of this Agreement pursuant to Section 10.2, as
directed by STI IgDraSol shall (a) return or destroy any materials, if any, (b) return to STI the Confidential Information, as set forth in Sections 2.8 and 7.5, and (c) deliver to STI, or destroy at STI’s request, the
Deliverables (in whatever stage of development or completion); provided that IgDraSol shall have the right to any and all right, title and interest to the STI Property developed pursuant to this Agreement that is not necessary or useful with respect
to the Products. STI shall provide reasonable cooperation in transferring the relevant STI Property to which IgDraSol has title pursuant to this Section 10.3.2. 
 11. GENERAL PROVISIONS 

11.1 Governing Law; Venue. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware,
without reference to any conflict of laws principles that would require the application of the laws of any other jurisdiction. The United Nations Convention on Contracts for the International Sale of Goods does not apply to this Agreement.

 11.2 Severability. If any provision of this Agreement is, for any reason, held to be invalid or unenforceable, the
other provisions of this Agreement will be unimpaired and the invalid or unenforceable provision will be deemed modified so that it is valid and enforceable to the maximum extent permitted by law. 

11.3 No Assignment. This Agreement and IgDraSol’s rights and obligations under this Agreement may not be assigned, delegated,
or otherwise transferred, in whole or in part, by operation of law or otherwise, by IgDraSol without STI’s express prior written consent. STI may assign this Agreement or any of its rights under this Agreement to any third party without

  
 8 

 Execution Version 
  

 
IgDraSol’s consent to any party that acquires all right, title and interest to the Products. In the case of any permitted assignment or transfer of or under this Agreement, this Agreement
shall be binding upon, and inure to the benefit of, the successors, executors, heirs, representatives, administrators and assigns of the Parties hereto. Any attempted assignment, delegation, or transfer in violation of the foregoing shall be null
and void. 
 11.4 Notices. Any notice or other communication required or permitted to be delivered to any party under
this Agreement shall be in writing and shall be deemed properly delivered, given and received: (a) if delivered by hand, when delivered; (b) if sent via facsimile with confirmation of receipt, when transmitted and receipt is confirmed;
(c) if sent by registered, certified or first class mail, the third business day after being sent; and (d) if sent by overnight delivery via a national courier service, one business day after being sent, in each case to the address or
facsimile telephone number set forth beneath the name of such party below (or to such other address or facsimile telephone number as such party shall have specified in a written notice given to the other parties hereto): 

If to IgDraSol: 
 IgDraSol, Inc. 
 11100 Warner Avenue, Suite 266, Fountain Valley, CA 92708

 Attn: Chief Executive Officer 
 with a copy (which shall not constitute notice) to: 
 Snell & Wilmer LLP

 600 Anton Blvd., Suite 1400 
 Costa Mesa, CA 92626 
 Attention: William Pedranti 

If to STI: 
 Sorrento Therapeutics, Inc. 
 6042 Cornerstone Ct. W. 

San Diego, CA 92121 
 Attn: Chief Executive Officer 
 with a copy (which shall not constitute notice)
to: 
 Cooley LLP 
 3175 Hanover Street 
 Palo Alto, CA 94304 

Attention: Glen Y. Sato 
 11.5 Remedies. The rights and remedies provided to each Party in this Agreement are cumulative and in addition to any other rights and remedies available to such Party at law or in equity.

 11.6 Construction. Section headings are included in this Agreement merely for convenience of reference; they are not
to be considered part of this Agreement or used in the interpretation of this Agreement. No rule of strict construction will be applied in the interpretation or construction of this Agreement. 

  
 9 

 Execution Version 
  

 11.7 Amendment. This Agreement may not be amended, modified, altered or
supplemented other than by means of a written instrument duly executed and delivered on behalf of all of the parties hereto. 

11.8 Waiver. 
 (a) No failure on the part of any person or entity to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any person or entity in exercising any power,
right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise
thereof or of any other power, right, privilege or remedy. 
 (b) No person or entity shall be deemed to have waived any
claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on
behalf of such person or entity; and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given. 
 11.9 Entire Agreement. This Agreement, including the Exhibit hereunder, is the final, complete, and exclusive agreement of the Parties with respect to the subject matter hereof and supersedes and
merges all prior or contemporaneous communications and understandings between the Parties. 
 11.10 Counterparts. This
Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which shall constitute together the same instrument. Each Party may execute this Agreement by facsimile transmission or in AdobeTM
Portable Document Format (PDF) sent by electronic mail. In addition, facsimile or PDF signatures of authorized signatories of either Party will be deemed to be original signatures and will be valid and binding, and delivery of a facsimile or PDF
signature by either Party will constitute due execution and delivery of this Agreement. 
 <Signature Page to Follow>

  
 10 

 Execution Version 
  

 IN WITNESS WHEREOF, the Parties have
executed this Services Agreement as of the Effective Date. 
  

									
	SORRENTO THERAPEUTICS, INC.	 		 	IGDRASOL, INC.
					
	By:	 	 /s/ Henry Ji
	 		 	By:	 	 /s/ Vuong Trieu

					
	Name:	 	 Henry Ji
	 		 	Name:	 	 Vuong Trieu

					
	Title:	 	 President and CEO
	 		 	Title:	 	 CEO

 Signature Page to Development Services Agreement 

  

 Execution Version 
  

 EXHIBIT A 

DEVELOPMENT PLAN 
 STI Contact: Gunnar Kaufmann 
 Services Manager: Chulho Park 

The total Fees for the Services shall be one million dollars. This shall include payments for full time employees as well as all out-of-pocket expenses.

 The goal of this agreement is to provide a development path for STI’s lead antibody product candidates and to recommend up to two
candidates for progression into IND enabling studies.
                                         
                                         
                                         
   
                                        

  

	 	1)	Project evaluation/review/prioritization/guidance/troubleshooting. 

  

	 	2)	Define development path for each program. 

  

	 	3)	                            
                                         
                                         
     

  

	 	4)	
                              
                                         
                                         
                                         
                                     

 

	 	5)	                            
                                         
                       

  

	 	6)	
                              
                                         
                                         
                                         
                         

  

	 	7)	                            
                                         

  

									
	 	  	Mar 1-31	 	  	Apr 1-20	 
			
	 R&D Expenses
	  	$	            	  	  	$	            	  
			
	 S,G&A expenses
	  				  			
		  	  
	  
	 	  	  
	  
	 
	 Total Expenses
	  	$	            	  	  	$	            	  
		  	  
	  
	 	  	  
	  
	 

  
 A-1EX-10.05

 Exhibit 10.05 
 Execution Version 
 VOTING AGREEMENT 

THIS VOTING AGREEMENT (“Voting Agreement”) is entered into as of
March 7, 2013, by and among SORRENTO THERAPEUTICS, INC., a Delaware corporation (“Sorrento”), IGDRASOL,
INC., a Delaware corporation (the “IgDraSol”) and the stockholder signatories hereto (“Stockholder”). 
 RECITALS 
 A. Stockholder is a holder of record and
the “beneficial owner” (within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) of certain shares of common stock of IgDraSol. 

B. Sorrento and IgDraSol are parties to an Option Agreement of even date herewith (the “Option Agreement”), which
provides Sorrento the right to acquire an exclusive option to acquire IgDraSol (the “Option”) pursuant to terms of that certain Agreement and Plan of Merger to be entered into among Sorrento, STI Merger Sub Inc., a Delaware
corporation (“Merger Sub”), IgDraSol and Vuong Trieu (solely in his capacity as the Stockholders’ Agent) (the “Merger Agreement”). The Merger Agreement provides (subject to the conditions set forth therein),
among other things, for the merger of Merger Sub into IgDraSol (the “Merger”). 
 C. In the Merger, each
outstanding share of common stock of IgDraSol (“IgDraSol Common Stock”) is to be converted into the right to receive shares of ordinary shares of Sorrento. 
 D. Stockholder is entering into this Voting Agreement in order to induce Sorrento to enter into the Option Agreement and, if exercised by Sorrento, to cause the Merger to be consummated pursuant to
the Merger Agreement. 
 AGREEMENT 

The parties to this Voting Agreement, intending to be legally bound, agree as follows: 

SECTION 1. CERTAIN DEFINITIONS 
 For purposes of this Voting Agreement: 
 (a) “Expiration
Date” shall mean the earliest of: (i) the date on which the Merger Agreement is terminated pursuant to Section 9 thereof; (ii) immediately following the adjournment of the meeting of the stockholders of IgDraSol at which the
Merger Agreement is adopted and approved by the stockholders of IgDraSol; (iii) expiration of the Option Period (as defined in the Option Agreement); or (iv) the date the Option Agreement is terminated pursuant to the terms thereof.

 (b) “Own” or to have acquired “Ownership” shall mean with respect to any security,
that a Stockholder: (i) is the record owner of such security; or (ii) is the “beneficial owner” (within the meaning of Rule 13d-3 under the Exchange Act) of such security. 

 (c) “Person” shall mean any individual, private or public
corporation (including not-for-profit), general or limited partnership, unlimited or limited liability company, joint venture, estate, trust, association, organization or other entity of any kind or nature, including a government or political
subdivision or an agency or instrumentality thereof. 
 (d) “Subject Securities” shall mean: (i) all
securities of IgDraSol (including all shares of IgDraSol Common Stock and all options, restricted stock units, warrants and other rights to acquire or convert into shares of IgDraSol Common Stock) Owned by Stockholder as of the date of this Voting
Agreement; and (ii) all additional securities of IgDraSol (including any additional shares of IgDraSol Common Stock and any additional options, restricted stock units, warrants and other rights to acquire or convert into shares of IgDraSol
Common Stock) of which Stockholder acquires Ownership during the Voting Period (as defined below), whether such acquisition is a result of purchases or other transfers of IgDraSol Common Stock to Stockholder or by virtue of a stock dividend, stock
split, recapitalization, reclassification, subdivision, combination or exchange of shares or by exercise of any rights to acquire or convert into IgDraSol Common Stock. 
 (e) “Transfer” of a security shall mean that a Person shall directly or indirectly: (i) sell, pledge, encumber, grant an option or other right with respect to, transfer or
dispose of such security or any interest in such security to any Person other than Sorrento; (ii) enters into an agreement or commitment contemplating the possible sale of, pledge of, encumbrance of, grant of an option with respect to, transfer
of or disposition of such security or any interest therein to any Person other than Sorrento; or (iii) reduces such Person’s beneficial ownership of, interest in or risk relating to such security. 

(f) “Voting Period” shall mean the period commencing on the date of this Voting Agreement and ending on the
Expiration Date. 
 SECTION 2. TRANSFER OF SUBJECT SECURITIES AND
VOTING RIGHTS 
 2.1 Restriction on Transfer of Subject Securities. Subject to
Section 2.3, during the Voting Period, Stockholder shall not, directly or indirectly, cause or permit any Transfer of any of the Subject Securities to any Person other than IgDraSol to be effected without the prior written consent of Sorrento.

 2.2 Restriction on Transfer of Voting Rights. During the Voting Period, Stockholder shall ensure that: (a) none
of the Subject Securities is deposited into a voting trust; and (b) no proxy is granted that is inconsistent with this Voting Agreement, and no voting agreement or similar agreement is entered into, with respect to any of the Subject
Securities. 
 2.3 Permitted Transfers. Section 2.1 shall not prohibit a Transfer of Subject Securities by
Stockholder if Stockholder is a partnership or limited liability company, to one or more partners or members of Stockholder or to an affiliated corporation under common control with Stockholder; provided, however, that a Transfer referred to
in this Section 2.3 shall be permitted only if, as a condition to such Transfer, the transferee agrees in a writing, satisfactory in form and substance to IgDraSol and Sorrento, to be bound by all of the terms of this Voting Agreement. Any
Transfer or purported Transfer of Subject Securities other than in accordance with Sections 2.1 and 2.3 shall be void ab initio and of no effect. 

  
 2 

 SECTION 3. VOTING OF SHARES 

3.1 VOTING COVENANT. Stockholder hereby agrees that, prior to the Expiration Date, at any meeting of
the stockholders of IgDraSol, however called, or at any adjournment or postponement thereof and on every action or approval by written consent of the stockholders of IgDraSol, unless otherwise directed in writing by Sorrento, Stockholder shall cause
any and all issued and outstanding shares of IgDraSol Common Stock Owned by Stockholder as of the record date with respect to such meeting to be voted: 
 (a) in favor of the Merger, the execution and delivery by IgDraSol of the Merger Agreement and the adoption and approval of the Merger Agreement and the terms thereof, in favor of each of the other
actions contemplated by the Merger Agreement and in favor of any action in furtherance of any of the foregoing; 
 (b) in
favor of any proposal to adjourn or postpone the meeting of the stockholders of IgDraSol to a later date if there are not sufficient votes for adoption of the Merger Agreement on the date on which such meeting is held; 

(c) against any action or agreement that would result in a material breach of any representation, warranty, covenant or obligation
of IgDraSol in the Merger Agreement; and 
 (d) against any action which is (i) intended to impede, interfere with,
delay, postpone, discourage or adversely affect the Merger or any of the other transactions contemplated by the Merger Agreement or this Voting Agreement, or (ii) would reasonably be expected, to impede, interfere with, materially delay,
materially postpone, discourage or adversely affect in any material way the Merger or any of the other transactions contemplated by the Merger Agreement or this Voting Agreement. 

Prior to the Expiration Date, Stockholder shall not enter into any agreement or understanding with any Person to vote or give
instructions in any manner inconsistent with clause “(a)”, clause “(b)”, clause “(c)” or clause “(d)” of the preceding sentence. 
 3.2 PROXY 
 (a) Contemporaneously with
the execution of this Voting Agreement: (i) Stockholder shall deliver to Sorrento a proxy in the form attached to this Voting Agreement as Exhibit A, which shall be irrevocable to the fullest extent permitted by law (at all times during
the Voting Period) with respect to the shares referred to therein (the “Proxy”); and (ii) if applicable, Stockholder shall cause to be delivered to Sorrento an additional proxy (in the form attached hereto as Exhibit A)
executed on behalf of the record owner of any outstanding shares of IgDraSol Common Stock that are Owned by Stockholder. 

(b) Stockholder shall not enter into any tender, voting or other agreement, or grant a proxy or power of attorney, with respect to
the Subject Securities that is inconsistent with this Voting Agreement or otherwise take any other action with respect to the Subject Securities that would in any way restrict, limit or interfere with the performance of Stockholder’s
obligations hereunder or the transactions contemplated hereby. 

  
 3 

 SECTION 4. REPRESENTATIONS AND WARRANTIES OF
STOCKHOLDER 
 Stockholder hereby represents and warrants to Sorrento as follows: 

4.1 Authorization, etc. Stockholder has the power, authority and capacity to execute and deliver this Voting Agreement and
the Proxy and to perform Stockholder’s obligations hereunder and thereunder. This Voting Agreement and the Proxy have been duly executed and delivered by Stockholder and, assuming the due authorization, execution and delivery of this Voting
Agreement by Sorrento, constitute legal, valid and binding obligations of Stockholder, enforceable against Stockholder in accordance with their terms, subject to: (a) laws of general application relating to bankruptcy, insolvency and the relief
of debtors; and (b) rules of law governing specific performance, injunctive relief and other equitable remedies. 
 4.2
No Conflicts or Consents. 
 (a) The execution and delivery of this Voting Agreement and the Proxy by Stockholder do
not, and the performance of this Voting Agreement and the Proxy by Stockholder will not: (i) conflict with or violate any law applicable to Stockholder or by which Stockholder or any of Stockholder’s properties is or may be bound or
affected; or (ii) result in or constitute (with or without notice or lapse of time) any breach of or default under, or give to any other Person (with or without notice or lapse of time) any right of termination, amendment, acceleration or
cancellation of, or result (with or without notice or lapse of time) in the creation of any material lien on any of the Subject Securities. 
 (b) The execution and delivery of this Voting Agreement and the Proxy by Stockholder do not, and the performance of this Voting Agreement and the Proxy by Stockholder will not, require any consent
of any Person. 
 4.3 Title to Securities. As of the date of this Voting Agreement, subject to any vesting or rights of
repurchase by IgDraSol, if any: (a) Stockholder holds of record (free and clear of any liens) the number of outstanding shares of IgDraSol Common Stock set forth under the heading “Shares Held of Record” on the signature page hereof;
(b) Stockholder holds (free and clear of any liens) the options, restricted stock units, warrants and other rights to acquire shares of IgDraSol Common Stock set forth under the heading “Options and Other Rights” on the signature page
hereof; (c) Stockholder Owns the additional securities of IgDraSol set forth under the heading “Additional Securities Beneficially Owned” on the signature page hereof; and (d) Stockholder does not directly or indirectly Own any
shares of capital stock or other securities of IgDraSol, or any option, restricted stock unit, warrant or other right to acquire (by purchase, conversion or otherwise) any shares of capital stock or other securities of IgDraSol, other than the
shares and options, restricted stock units, warrants and other rights set forth on the signature page hereof. 
 4.4 Accuracy
of Representations. The representations and warranties contained in this Voting Agreement are accurate in all respects as of the date of this Voting Agreement, and will be accurate in all respects at all times prior to the Expiration Date as if
made as of any such time or date. 

  
 4 

 SECTION 5. MISCELLANEOUS 

5.1 Stockholder Information. Stockholder hereby agrees to permit Sorrento and IgDraSol to publish and disclose in the proxy
statement and any other public disclosure that Sorrento and IgDraSol mutually determine to be necessary or desirable in connection with the Merger and any other transactions contemplated by the Merger Agreement Stockholder’s identity and
ownership of shares of IgDraSol Common Stock and the nature of Stockholder’s commitments, arrangements and understandings under this Voting Agreement. 
 5.2 Further Assurances. From time to time and without additional consideration, Stockholder shall execute and deliver, or cause to be executed and delivered, such additional transfers, assignments,
endorsements, proxies, consents and other instruments, and shall take such further actions, as Sorrento may reasonably request for the purpose of carrying out and furthering the intent of this Voting Agreement. 

5.3 Expenses. All costs and expenses incurred in connection with the transactions contemplated by this Voting Agreement shall be
paid by the party incurring such costs and expenses. 
 5.4 Notices. Any notice or other communication required or
permitted to be delivered to any party under this Voting Agreement shall be in writing and shall be deemed properly delivered, given and received: (a) if delivered by hand, when delivered; (b) if sent via facsimile before 5:00 p.m.
(Pacific time) with confirmation of receipt, when transmitted and receipt is confirmed; (c) if sent by registered, certified or first class mail, the third business day after being sent; and (d) if sent by overnight delivery via a national
courier service, one business day after being sent, in each case to the address or facsimile telephone number set forth beneath the name of such party below (or to such other address or facsimile telephone number as such party shall have specified
in a written notice given to the other parties hereto): 
 if to Stockholder: 

at the address set forth on the signature page hereof; and 
 if to Sorrento: 
 Sorrento Therapeutics, Inc. 

6042 Cornerstone Court West, Suite B 
 San Diego, CA 92121 
 Attn.: Chief Financial Officer 

Tel. No.: (858) 210-3700 
 Fax No.: (858) 210-3759 

  
 5 

 with a copy (which shall not constitute notice) to: 

Cooley LLP 

3175 Hanover Street 
 Palo Alto, CA 94304 
 Attn.: Glen Y. Sato 

Fax No.: (650) 849-7400 
 if to IgDraSol: 
 IgDraSol, Inc. 

1110 Warner Avenue, Suite 266 
 Fountain Valley, CA 92708 
 Attn.: President 

Fax No.: (714) 445-0127 
 with a copy (which shall not constitute notice) to: 
 Snell & Wilmer
L.L.P 
 600 Anton Blvd., Suite 1400 
 Costa Mesa, CA 92626 
 Attn.: William Pedranti 

Fax No.: (714) 427-7799 
 5.5 Severability. In the event that any provision of this Voting Agreement, or the application of any such provision to any Person or set of circumstances, shall be determined to be invalid,
unlawful, void or unenforceable to any extent, the remainder of this Voting Agreement, and the application of such provision to Persons or circumstances other than those as to which it is determined to be invalid, unlawful, void or unenforceable,
shall not be impaired or otherwise affected and shall continue to be valid and enforceable to the fullest extent permitted by law. 
 5.6 Entire Agreement. This Voting Agreement, the Proxy, the Merger Agreement, the Option Agreement and any other agreements referred to herein set forth the entire understanding of the parties
hereto relating to the subject matter hereof and thereof and supersede all prior agreements and understandings among or between any of the parties relating to the subject matter hereof and thereof. 

5.7 Amendments. This Voting Agreement may not be amended, modified, altered or supplemented other than by means of a written
instrument duly executed and delivered on behalf of all of the parties hereto. 
 5.8 Assignment; Binding Effect; No Third
Party Rights. Except as provided herein, neither this Voting Agreement nor any of the interests or obligations hereunder may be assigned or delegated by Stockholder, and any attempted or purported assignment or delegation of any of such
interests or obligations shall be void. Subject to the preceding sentence, this Voting Agreement shall be binding upon Stockholder and Stockholder’s successors and assigns, and shall inure to the benefit of Sorrento and its successors and
assigns. Without limiting any of the restrictions set forth in Section 2, Section 3 or elsewhere in this Voting Agreement, this Voting Agreement shall be binding upon any Person to whom any Subject Securities are transferred. Nothing in
this Voting Agreement is intended to confer on any Person (other than Sorrento and its successors and assigns) any rights or remedies of any nature. 

  
 6 

 5.9 Specific Performance. The parties agree that irreparable damage would occur in
the event that any of the provisions of this Voting Agreement or the Proxy were not performed in accordance with its specific terms or were otherwise breached. Stockholder agrees that, in the event of any breach or threatened breach by Stockholder
of any covenant or obligation contained in this Voting Agreement or in the Proxy, Sorrento shall be entitled (in addition to any other remedy that may be available to it, including monetary damages) to obtain: (a) a decree or order of specific
performance to enforce the observance and performance of such covenant or obligation; and (b) an injunction restraining such breach or threatened breach. Stockholder further agrees that neither Sorrento nor any other Person shall be required to
obtain, furnish or post any bond or similar instrument in connection with or as a condition to obtaining any remedy referred to in this Section 5.9, and Stockholder irrevocably waives any right he or it may have to require the obtaining,
furnishing or posting of any such bond or similar instrument. 
 5.10 Attorneys’ Fees. If any action or proceeding
relating to this Voting Agreement or the enforcement of any provision of this Voting Agreement is brought against any party hereto, the prevailing party shall be entitled to recover reasonable attorneys’ fees, costs and disbursements (in
addition to any other relief to which the prevailing party may be entitled). 
 5.11 Non-Exclusivity. The rights and
remedies of Sorrento under this Voting Agreement are not exclusive of or limited by any other rights or remedies which it may have, whether at law, in equity, by contract or otherwise, all of which shall be cumulative (and not alternative).

 5.12 Governing Law; Jurisdiction; Waiver of Jury Trial. This Voting Agreement and the Proxy shall be construed in
accordance with, and governed in all respects by, the internal laws of the State of Delaware, (without giving effect to principles of conflicts of laws). Any Legal Proceeding (as defined below) relating to this Agreement or the enforcement of any
provision of this Agreement (including a Legal Proceeding based upon intentional or willful misrepresentation or fraud) may be brought or otherwise commenced in any state or federal court located in the State of California. Each party to this
Agreement: (i) expressly and irrevocably consents and submits to the jurisdiction of each state and federal court located in the State of California (and each appellate court located in the State of California) in connection with any such Legal
Proceeding; (ii) agrees that each state and federal court located in the State of California shall be deemed to be a convenient forum; and (iii) agrees not to assert (by way of motion, as a defense or otherwise), in any such Legal
Proceeding commenced in any state or federal court located in the State of California, any claim that such party is not subject personally to the jurisdiction of such court, that such Legal Proceeding has been brought in an inconvenient forum, that
the venue of such proceeding is improper or that this Agreement or the subject matter of this Agreement may not be enforced in or by such court. For purposes of this section, “Legal Proceeding” shall mean any action, suit,
litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before, or otherwise
involving, any court or other Governmental Body or any arbitrator or arbitration panel. 

  
 7 

 5.13 Waiver of Jury Trial. Each of the parties hereto hereby irrevocably waives any
and all right to trial by jury in any Legal Proceeding arising out of or related to this Voting Agreement or the transactions contemplated hereby. 
 5.14 Counterparts; Exchanges by Facsimile or Electronic Delivery. This Voting Agreement may be executed in separate counterparts, each of which when so executed and delivered shall be an original,
but all such counterparts shall together constitute one and the same instrument. The exchange of a fully executed Voting Agreement (in counterparts or otherwise) by facsimile or electronic delivery shall be sufficient to bind the parties to the
terms and conditions of this Voting Agreement. 
 5.15 Headings. The headings contained in this Voting Agreement are for
convenience of reference only, shall not be deemed to be a part of this Voting Agreement and shall not be referred to in connection with the construction or interpretation of this Voting Agreement. 

5.16 Waiver. Subject to the remainder of this Section 5.16, at any time prior to the Expiration Date, any party hereto may:
(a) extend the time for the performance of any of the obligations or other acts of the other parties to this Voting Agreement; (b) waive any inaccuracy in or breach of any representation, warranty, covenant or obligation of the other party
in this Voting Agreement or in any document delivered pursuant to this Voting Agreement; and (c) waive compliance with any covenant, obligation or condition for the benefit of such party contained in this Voting Agreement. No failure on the
part of any Person to exercise any power, right, privilege or remedy under this Voting Agreement, and no delay on the part of any Person in exercising any power, right, privilege or remedy under this Voting Agreement, shall operate as a waiver of
such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. No Person shall be deemed
to have waived any claim arising out of this Voting Agreement, or any power, right, privilege or remedy under this Voting Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument
duly executed and delivered on behalf of such Person; and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given. 
 5.17 Independence of Obligations. The covenants and obligations of Stockholder set forth in this Voting Agreement shall be construed as independent of any other contract between Stockholder, on the
one hand, and IgDraSol or Sorrento, on the other. The existence of any claim or cause of action by Stockholder against IgDraSol or Sorrento shall not constitute a defense to the enforcement of any of such covenants or obligations against
Stockholder. Nothing in this Voting Agreement shall limit any of the rights or remedies of Sorrento under the Merger Agreement, or any of the rights or remedies of Sorrento or any of the obligations of Stockholder under any agreement between
Stockholder and Sorrento or any certificate or instrument executed by Stockholder in favor of Sorrento; and nothing in the Merger Agreement or in any other such agreement, certificate or instrument, shall limit any of the rights or remedies of
Sorrento or any of the obligations of Stockholder under this Voting Agreement. 
 5.18 Other Capacities. Notwithstanding
any provision of this Voting Agreement to the contrary, nothing in this Voting Agreement shall limit or restrict Stockholder from acting in good faith in Stockholder’s capacity as a director or officer of IgDraSol (it being understood that this
Voting Agreement shall apply to Stockholder solely in Stockholder’s capacity as a stockholder of IgDraSol). 

  
 8 

 5.19 Construction. 

(a) For purposes of this Voting Agreement, whenever the context requires: the singular number shall include the plural, and vice
versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include the masculine and feminine genders. 

(b) The parties hereto agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting
party shall not be applied in the construction or interpretation of this Voting Agreement. 
 (c) As used in this Voting
Agreement, the words “include” and “including,” and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words “without limitation.” 

(d) Except as otherwise indicated, all references in this Voting Agreement to “Sections” and “Exhibits” are
intended to refer to Sections of this Voting Agreement and Exhibits to this Voting Agreement. 
 [Remainder of page
intentionally left blank.] 

  
 9 

 IN WITNESS WHEREOF, Sorrento and
Stockholder have caused this Voting Agreement to be executed as of the date first written above. 
  

	
	SORRENTO THERAPEUTICS, INC.
	
	 /s/ Henry Ji

	By
	 President and CEO

	Title
	
	IGDRASOL, INC.
	
	 /s/ Vuong Trieu

	By
	 CEO

	Title

 Voting Agreement Signature Page 

 IN WITNESS WHEREOF, Sorrento and
Stockholder have caused this Voting Agreement to be executed as of the date first written above. 
  

			
	SORRENTO THERAPEUTICS, INC.
		
	Signature:	 	 /s/ Henry Ji

		
	Print Name:	 	Henry Ji
		
	Title:	 	President and CEO
	
	STOCKHOLDER
		
	Signature:	 	 /s/ Bassil Dahiyat

		
	Print Name:	 	Bassil Dahiyat
		
	Address:	 	 3848 Canyon Lane
 Altadena, CA
91001

		
	Facsimile:	 	

  

					
	Shares Held of Record	  	Options and Other Rights	  	Additional Securities
Beneficially 
Owned
	125,000	  		  	

 Voting Agreement Signature Page 

 IN WITNESS WHEREOF, Sorrento and
Stockholder have caused this Voting Agreement to be executed as of the date first written above. 
  

			
	SORRENTO THERAPEUTICS, INC.
		
	Signature:	 	 /s/ Henry Ji

		
	Print Name:	 	Henry Ji
		
	Title:	 	President and CEO
	
	STOCKHOLDER
		
	Signature:	 	 /s/ Chao Hsiao

		
	Print Name:	 	Chao Hsiao
		
	Address:	 	 526 S. Orange Ave. #B
 Monterey
Park, CA 91755

		
	Facsimile:	 	

  

					
	Shares Held of Record	  	Options and Other Rights	  	Additional Securities
Beneficially 
Owned
	121,875	  		  	

 Voting Agreement Signature Page 

 IN WITNESS WHEREOF, Sorrento and
Stockholder have caused this Voting Agreement to be executed as of the date first written above. 
  

			
	SORRENTO THERAPEUTICS, INC.
		
	Signature:	 	 /s/ Henry Ji

		
	Print Name:	 	Henry Ji
		
	Title:	 	President and CEO
	
	STOCKHOLDER
		
	Signature:	 	 /s/ Kouros Motamed

		
	Print Name:	 	Kouros Motamed
		
	Address:	 	 25 Palatine #433
 Irvine, CA
92612

		
	Facsimile:	 	

  

					
	Shares Held of Record	  	Options and Other Rights	  	Additional Securities
Beneficially 
Owned
	487,500	  		  	

 Voting Agreement Signature Page 

 IN WITNESS WHEREOF, Sorrento and
Stockholder have caused this Voting Agreement to be executed as of the date first written above. 
  

			
	SORRENTO THERAPEUTICS, INC.
		
	Signature:	 	 /s/ Henry Ji

		
	Print Name:	 	Henry Ji
		
	Title:	 	President and CEO
	
	STOCKHOLDER
		
	Signature:	 	 /s/ Vuong Trieu

		
	Print Name:	 	Vuong Trieu
		
	Address:	 	 4003 Jim Bowie
 Agoura Hills,
CA 91301

		
	Facsimile:	 	

  

					
	Shares Held of Record	  	Options and Other Rights	  	Additional Securities
Beneficially 
Owned
	2,925,000	  	Warrant for 416,666	  	Convertible Promissory Note for
 $250,000

 Voting Agreement Signature Page 

 IN WITNESS WHEREOF, Sorrento and
Stockholder have caused this Voting Agreement to be executed as of the date first written above. 
  

			
	SORRENTO THERAPEUTICS, INC.
		
	Signature:	 	 /s/ Henry Ji

		
	Print Name:	 	Henry Ji
		
	Title:	 	President and CEO
	
	STOCKHOLDER
		
	Signature:	 	 /s/ Larn Hwang

		
	Print Name:	 	Larn Hwang
		
	Address:	 	 131 S. Second Ave. #A
 Arcadia,
CA 91006

		
	Facsimile:	 	

  

					
	Shares Held of Record	  	Options and Other Rights	  	Additional Securities
Beneficially 
Owned
	487,500	  		  	

 Voting Agreement Signature Page 

 IN WITNESS WHEREOF, Sorrento and
Stockholder have caused this Voting Agreement to be executed as of the date first written above. 
  

			
	SORRENTO THERAPEUTICS, INC.
		
	Signature:	 	 /s/ Henry Ji

		
	Print Name:	 	Henry Ji
		
	Title:	 	President and CEO
	
	STOCKHOLDER
		
	Signature:	 	 /s/ Jason Dekker

		
	Print Name:	 	Jason Dekker
		
	Address:	 	 1001 S. Meadows Pkwy, Apt. 1532

Reno, NV 89521

		
	Facsimile:	 	

  

					
	Shares Held of Record	  	Options and Other Rights	  	Additional Securities
Beneficially 
Owned
	487,500	  	Warrant for 8,333	  	Convertible Promissory Note for
 $5,000

 Voting Agreement Signature Page 

 EXHIBIT A 

FORM OF IRREVOCABLE PROXY 

 IRREVOCABLE PROXY 

The undersigned stockholder (the “Stockholder”) of IgDraSol, Inc., a Delaware corporation (the
“IgDraSol”), hereby irrevocably (to the fullest extent permitted by law) appoints and constitutes Sorrento Therapeutics, Inc., a Delaware corporation (“Sorrento”), and Dr. Henry Ji and Richard Vincent, solely
in their capacities as executive officers of Sorrento, and each of them, the attorneys and proxies of the Stockholder, with full power of substitution and resubstitution, to the full extent of the Stockholder’s rights with respect to the
outstanding shares of capital stock of IgDraSol owned of record by the Stockholder as of the date of this proxy, which shares are specified in this proxy, and all shares of capital stock of IgDraSol that may be owned of record by the Stockholder
after the date of this proxy. (The shares of the capital stock of IgDraSol referred to in the immediately preceding sentence are referred to as the “Shares.”) Upon the execution of this proxy, all prior proxies given by the
Stockholder with respect to any of the Shares are hereby revoked, and the Stockholder agrees that no subsequent proxies inconsistent with this Proxy will be given with respect to any of the Shares. 

This proxy is irrevocable, is coupled with an interest and is granted in connection with, and as security for, the Voting Agreement,
dated as of the date hereof, by and among Sorrento, IgDraSol and the Stockholder (the “Voting Agreement”), and is granted in consideration of Sorrento entering into the Agreement and Plan of Merger, dated as of the date hereof,
among Sorrento, STI Merger Sub Inc., a Delaware corporation, IgDraSol and Vuong Trieu as the Stockholders’ Agent. This proxy will terminate on the Expiration Date (as defined in the Voting Agreement). 

Prior to the Expiration Date, the attorneys and proxies named above will be empowered, and may exercise this proxy, to vote any Shares
owned by the undersigned, at any meeting of the stockholders of IgDraSol, however called, or at any adjournment or postponement thereof and on every action or approval by written consent of the stockholders of IgDraSol: 

(a) in favor of the Merger, the execution and delivery by IgDraSol of the Merger Agreement and the adoption and
approval of the Merger Agreement and the terms thereof, in favor of each of the other actions contemplated by the Merger Agreement and in favor of any action in furtherance of any of the foregoing; 

(b) in favor of any proposal to adjourn or postpone the meeting of the stockholders of IgDraSol to a later date if
there are not sufficient votes for adoption of the Merger Agreement on the date on which such meeting is held; 

(c) against any action or agreement that would result in a material breach of any representation, warranty,
covenant or obligation of IgDraSol in the Merger Agreement; and 
 (d) against any action which is
(i) intended to impede, interfere with, delay, postpone, discourage or adversely affect the Merger or any of the other transactions contemplated by the Merger Agreement or this Voting Agreement, or (ii) would reasonably be expected, to
impede, interfere with, materially delay, materially postpone, discourage or adversely affect in any material way the Merger or any of the other transactions contemplated by the Merger Agreement or this Voting Agreement. 

Proxy 

 The Stockholder may vote the Shares on all other matters not referred to in this proxy, and
the attorneys and proxies named above may not exercise this proxy with respect to such other matters. 
 This proxy shall be
binding upon the heirs, estate, executors, personal representatives, successors and assigns of the Stockholder (including any transferee of any of the Shares). 
 Any term or provision of this proxy that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this
proxy or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. Upon such determination that any term or provision is invalid, illegal or incapable of being enforced, the parties hereto
shall negotiate in good faith to modify this proxy so as to effect the original intent of the parties as closely as possible in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the fullest extent possible.

  

							
	Dated:     , 2013	 		 	STOCKHOLDER
			
		 		 	[                    ]
				
		 		 	By:	 	
		 		 	Its:	 	
				
		 		 	By:	 	
		 		 	Its:	 	
				
		 		 	Signature:	 	  

				
		 		 	Print Name:	 	  

				
		 		 	Title:	 	  

			
		 		 	Number of shares of common stock of IgDraSol owned of record as of the date of this proxy:
			
		 		 	  

 Proxy

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}]]